Luspatercept Lowers the Transfusion Burden in Patients With Myelofibrosis-Associated Anemia
Aaron Gerds, MD discusses the results of a phase II BELIEVE study of luspatercept as treatment of patients with myelofibrosis-associated anemia.
Aaron Gerds, MD, assistant professor of Medicine, Cleveland Clinic - Taussig Cancer Center, discussed the results of a phase II BELIEVE study of luspatercept (Reblozyl) as treatment of patients with myelofibrosis-associated anemia.
Every cohort in the study had responses to treatment with luspatercept. Additionally, luspatercept successfully reduced the transfusion burden in 21.4% of the study subjects compared only 4.5% of those who received placebo, meeting the primary end point of the study.
Gerd notes, however, that responses were higher in patients who received ruxolitinib (Jakafi) along with the luspatercept.
<< View more content from the 2019 American Society of Hematology Annual Meeting
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
